To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus - Trial NCT01300208
Access comprehensive clinical trial information for NCT01300208 through Pure Global AI's free database. This Phase 2 trial is sponsored by Amgen and is currently Completed. The study focuses on Cutaneous Lupus Erythematosus. Target enrollment is 48 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Amgen
Timeline & Enrollment
Phase 2
Oct 01, 2010
Mar 01, 2013
Primary Outcome
Laboratory values from chemistry, hematology, urinalysis, inflammation/immunology panel that reveal clinically significant abnormalities and that may constitute a safety concern
Summary
This is the first study in cutaneous lupus erythematosus subjects to evaluate the safety,
 tolerability, pharmacokinetics, pharmacodynamics, and efficacy of CC-11050.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT01300208
Non-Device Trial